Davis Polk advised the representatives of the several underwriters in the offering. Adagio Therapeutics, Inc. executed the initial public offering of 20,930,000 shares of its common stock at...
Adagio Therapeutics’ $356 Million Initial Public Offering
RxSight’s $117.6 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering. RxSight, Inc. executed an initial public offering of 7,350,000 shares of common stock at $16.00 per...
Tenaya Therapeutics’ $207 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in the offering while Wilson Sonsini Goodrich & Rosati represented Tenaya Therapeutics. Tenaya Therapeutics, Inc. executed the initial...
SOPHiA GENETICS’ $234 Million Initial Public Offering on Nasdaq
Homburger and Davis Polk advised SOPHiA GENETICS on the deal. Lenz & Staehelin acted as Swiss counsel to the underwriters. SOPHiA GENETICS SA listed its shares...
Acutus Medical’s $77 Million Shares Offering
Davis Polk advised Acutus Medical on the deal. Acutus Medical, Inc. executed its SEC-registered public offering of 5,500,000 shares of common stock for an aggregate price...
Sight Sciences’ $240 Million Initial Public Offering
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...
IDEAYA Biosciences’ $92 Million Common Stock Offering
Latham & Watkins advised IDEAYA Biosciences, while Davis Polk advised the underwriters in the offering. IDEAYA Biosciences, Inc. executed its public offering of 5,333,333 shares of common...
Arbor Investments’ Acquisition of Bagel Boy
Winston & Strawn represented Arbor Investments and its portfolio company Crown Bakeries in the transaction. Arbor Investments and its portfolio company Crown Bakeries announced the acquisition of...
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
Novo Nordisk’s Acquisition of Neotope Neuroscience
Davis Polk, working alongside Matheson, advised Novo Nordisk on the deal. Novo Nordisk A/S completed its acquisition of Neotope Neuroscience Limited from Prothena Biosciences Limited for...
GH Research’s $184 Million Initial Public Offering
Dentons and Davis Polk advised GH Research PLC on the IPO. GH Research PLC executed its SEC-registered initial public offering of 11,499,999 ordinary shares for total...
Theravance Biopharma’s $100.5 Million Shares Offering
Davis Polk advised the underwriters in the offering. Theravance Biopharma, Inc. executed its $100.5 million public offering of ordinary shares. Theravance Biopharma’s ordinary shares are listed on the Nasdaq...